Shots:
Health Canada has granted NOC to Bevqolva (bevacizumab), a biosimilar version of Genentech’s Avastin
Bevacizumab, a humanized mAb, inhibits angiogenesis by blocking VEGF-A to slow tumor vascular growth in cancers like colorectal and lung. Marketed by Roche/Genentech as Avastin, it is available in 100 mg and 400 mg formulations
In 2025, Bevqolva received MHRA approval and was launched in the…
